source
- Novo Nordisk acquires three early-stage obesity programs from KallyopeNovo Nordisk announced the purchase of three early-stage obesity drug programs from New York‑based biotech Kallyope, expanding its metabolic pipeline. The acquired assets are not GLP‑1 incretins.…
- Alkermes reports promising Phase 1b results for orexin agonist ALKS 7290 in ADHDAlkermes presented data from a Phase 1b study that evaluated its orexin-based compound ALKS 7290 in adults with attention-deficit/hyperactivity disorder. The trial enrolled 50 participants who rece…